Integra LifeSciences Holdings Corporation
04/15/2026 | Press release | Distributed by Public on 04/15/2026 14:24
Material Agreement (Form 8-K)
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
As previously disclosed, on December 18, 2018, certain subsidiaries of Integra LifeSciences Holdings Corporation, a Delaware corporation (the "Company"), entered into a $150 million accounts receivable securitization facility (the "A/R Facility") to reduce outstanding revolving borrowings under the Company's senior credit facility and to provide additional liquidity and funding for the ongoing business needs of the Company and its subsidiaries.
The documentation for the A/R Facility included (i) a Receivables Financing Agreement (the "RFA") entered into by and among Integra Receivables LLC, a Delaware limited liability company and a bankruptcy-remote special purpose entity that is an indirect, wholly-owned subsidiary of the Company (the "Borrower"), Integra LifeSciences Sales LLC ("ILS Sales"), as Servicer (the "Servicer"), PNC Bank, National Association ("PNC"), as Administrative Agent, PNC Capital Markets LLC, as Structuring Agent, and certain lenders and group agents that are parties thereto from time to time and (ii) a Purchase and Sale Agreement (the "PSA") by and among ILS Sales, Integra LifeSciences Corporation, and certain other subsidiaries of the Company party thereto from time to time, as Originators, the Servicer and the Borrower.
On April 10, 2026, (i) the Borrower and ILS Sales entered into Amendment No. 8 to Receivables Financing Agreement (the "RFA Amendment"), by and among the Borrower, ILS Sales, as Servicer, PNC, as Administrative Agent and Committed Lender, The Bank of Nova Scotia, as Committed Lender and Group Agent, PNC Capital Markets LLC, as Structuring Agent, and certain lenders and group agents that are parties thereto from time to time and (ii) the Borrower and ILS Sales entered into Amendment No. 1 to Purchase and Sale Agreement(the "PSA Amendment," and together with the RFA Amendment, the "April 2026 Amendments"), by and between the Borrower, as Buyer and ILS Sales, as Servicer, and acknowledged and agreed by PNC, as Administrative Agent.
The RFA Amendment, among other things, extends the scheduled termination date of the A/R Facility to April 10, 2029, and implements amendments to certain customary representations and covenants under the RFA and the customary concentration limits applicable to the receivables in the A/R Facility. The PSA Amendment implements amendments to certain customary representations and covenants under the PSA.
The foregoing descriptions of the RFA Amendment and the PSA Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the RFA Amendment and the PSA Amendment, which will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the fiscal period ended March 31, 2026.
Integra LifeSciences Holdings Corporation published this content on April 15, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 15, 2026 at 20:24 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]